Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb, discusses AI's impact on drug discovery with a16z Bio + Health partner Jorge Conde. They explore AI integration strategies, emerging modalities, and tips for startups partnering with biopharma firms.

Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb, joins Jorge Conde of a16z to discuss the rapidly evolving role of AI in biopharma. They explore how technology serves as a competitive advantage and delve into generative AI's impact on drug development, particularly in cancer treatments. The conversation highlights the importance of agile partnerships in innovation and addresses the challenges of integrating AI into regulated healthcare, emphasizing the need for responsible practices and effective data management.